Baird Medical Announces First Microwave Ablation Procedures Using Its Technology in Vietnam and Argentina

Rhea-AI Summary

Baird Medical (NASDAQ: BDMD) announced successful first microwave ablation (MWA) procedures using its technology in Vietnam and Argentina.

The thyroid case in Vietnam and liver ablation in Argentina mark entry into two new markets, supporting Baird Medical's global expansion of minimally invasive treatment options.

Positive

• First microwave ablation procedures completed in Vietnam and Argentina using company technology
• Entry into two new international markets supports global expansion strategy
• Clinical use in both thyroid nodule and liver ablation broadens application profile

Negative

• None.

News Market Reaction – BDMD

+7.55% 3.1x vol

7 alerts

+7.55% News Effect

+15.7% Peak Tracked

-7.8% Trough Tracked

+$4M Valuation Impact

$54.11M Market Cap

3.1x Rel. Volume

On the day this news was published, BDMD gained 7.55%, reflecting a notable positive market reaction. Argus tracked a peak move of +15.7% during that session. Argus tracked a trough of -7.8% from its starting point during tracking. Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $4M to the company's valuation, bringing the market cap to $54.11M at that time. Trading volume was very high at 3.1x the daily average, suggesting strong buying interest.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved +7.5% in the session following this news. A strong positive reaction aligns with BDM...

Analysis

The stock moved +7.5% in the session following this news. A strong positive reaction aligns with BDMD’s expansion milestones, as its microwave ablation technology reached new markets while shares remained far below the 52-week high. Shelf capacity of up to US$50,000,000 remains a key dilution risk if tapped.

Key Figures

Shelf registration size: US$50,000,000 Revenue: $31.5M Revenue: $37.0M +5 more

8 metrics

Shelf registration size US$50,000,000 Form F-3 shelf prospectus filed May 22, 2026

Revenue $31.5M Full year 2023 per F-3 prospectus

Revenue $37.0M Full year 2024 per F-3 prospectus

Revenue $22.5M Full year 2025 per F-3 prospectus

Net income $10.7M Full year 2023 per F-3 prospectus

Net income $12.6M Full year 2024 per F-3 prospectus

Net loss $27.5M Full year 2025 per F-3 prospectus

Ordinary shares outstanding 42,208,763 As disclosed in Form F-3 prospectus

Historical Context

5 past events · Latest: Jun 09 ()

5 events

Date	Event	Sentiment	24h Move	Catalyst
Jun 09	HQ relocation		-1.4%	Announced move of global headquarters to New York City for U.S. expansion.
Apr 29	Full-year earnings		+1.8%	Reported 2025 revenue decline with operating loss and U.S. expansion initiatives.
Mar 16	Clinical workshops		+0.8%	Expert-led training workshops in Indonesia to support MWA adoption.
Mar 12	Regulatory clearance		-14.3%	Regulatory clearance of microwave ablation systems in Argentina.
Mar 09	Conference showcase		-7.4%	Showcased MWA technology and KOL engagement at NASIT 2026 in the U.S.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

microwave ablation, interventional radiology, form f-3, hfCAA, +2 more

6 terms

microwave ablation medical

"Baird Medical's minimally invasive microwave ablation technology NEW YORK"

Microwave ablation is a medical procedure that uses focused microwave energy to heat and destroy abnormal tissue, such as tumors, through a needle-like probe inserted into the body; think of it as using a tiny, targeted microwave oven to cook away problem cells without large incisions. It matters to investors because it represents a growing category of minimally invasive treatments that can reduce hospital stays, create demand for specialized devices and disposables, and influence reimbursement and adoption trends in healthcare markets.

interventional radiology medical

"physician in charge of the Interventional Radiology Unit, to treat a benign"

Interventional radiology is a medical specialty that uses imaging tools (like X-rays, CT scans or ultrasound) as a live map to guide tiny instruments through small skin openings to diagnose or treat problems inside the body, replacing larger surgeries. For investors, it matters because these image-guided procedures often cut recovery time, reduce hospital stays and create steady demand for specialized devices, imaging equipment and related services, affecting healthcare costs and industry revenues.

form f-3 regulatory

"filed a Form F-3 shelf prospectus to offer up to"

Form F-3 is a U.S. securities filing that lets eligible foreign companies pre-register and then quickly sell shares or other securities to raise money, because they already meet ongoing reporting and size tests. For investors it signals that the company is up-to-date with regulatory disclosure and has an efficient way to issue new securities — similar to a pre-approved credit line — which can mean faster capital raises but also potential dilution of existing holdings.

hfCAA regulatory

"highlights China-specific regulatory risks including HFCAA, CSRC filing requirements"

The HFCAA is a U.S. law that requires companies listed on U.S. stock exchanges to allow their auditors to be inspected by U.S. regulators; if a company’s auditors can’t be reviewed for several years, the company risks being removed from U.S. markets. For investors, it matters because the law increases transparency and audit oversight—think of it as a safety inspection for a car—while also creating a clear regulatory trigger that can affect a stock’s availability and price if compliance can’t be shown.

pcaob inspection regulatory

"HFCAA/PCAOB inspection risks and summarizes business focus"

PCAOB inspection is a review carried out by the Public Company Accounting Oversight Board of an auditor’s work and processes for public companies, checking that audits are performed correctly and follow professional rules. For investors, these inspections act like safety checks on the people who verify a company’s financial health: they reveal weaknesses that could hide mistakes or fraud, can prompt fixes or regulatory action, and influence how much confidence and risk investors assign to a company.

csrc filing requirements regulatory

"including HFCAA, CSRC filing requirements and cash-transfer restrictions"

Requirements set by the China Securities Regulatory Commission (CSRC) that specify which documents, disclosures and approvals publicly traded companies and market participants must submit to the regulator. Like traffic rules for corporate information, they ensure companies report financial results, major transactions, fundraising and other material events so investors can compare firms, assess risk and avoid surprise losses; failing to follow them can delay deals, trigger fines or reduce investor confidence.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

First procedures in two new markets highlight growing global adoption of Baird Medical's minimally invasive microwave ablation technology

NEW YORK, June 29, 2026 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or the "Company"), a market leader in minimally invasive Microwave Ablation (MWA) technology, today announced the successful completion of the first procedures using its MWA technology in Vietnam and Argentina.

In Vietnam, the first clinical case using the Company's MWA technology was completed at Lac Viet Friendship Hospital on June 18. The procedure was performed by Dr. Dinh Xuan Ha, Deputy Head of Diagnostic Imaging and physician in charge of the Interventional Radiology Unit, to treat a benign thyroid nodule. Dr. Dinh Xuan Ha is an experienced specialist in diagnostic imaging, ultrasound, and image-guided minimally invasive procedures.

In Argentina, Dr. Eduardo Houghton, Head of General Surgery at Hospital General de Agudos Bernardino Rivadavia in Buenos Aires, Argentina, used the Company's MWA technology to perform a successful liver ablation procedure on June 15^th. Dr. Houghton brings extensive clinical and academic experience in general surgery, minimally invasive and percutaneous surgery, image-guided procedures, and hepatobiliary-pancreatic surgery.

"The successful introduction of our microwave ablation technology in both Vietnam and Argentina reflect Baird Medical's continued focus on expanding access to minimally invasive treatment options worldwide," said Haimei Wu, Chairwoman & CEO of Baird Medical. "These landmark procedures represent an important step forward in our global expansion strategy. We look forward to continued collaboration with clinical partners to bring our technology to more patients who may benefit from less invasive alternatives to traditional surgery."

"Our goal is to offer the most appropriate treatment option for each patient based on their individual condition," said Dr. Dinh Xuan Ha.  "Microwave ablation allows for highly targeted treatment through a minimally invasive approach with little to no visible scarring, as well as relatively short procedure and recovery time. We are encouraged with the outcome of this first case and look forward to incorporating microwave ablation into our practice moving forward."

Microwave ablation is a minimally invasive procedure that uses thermal energy to treat targeted tissue through a small needle-like applicator. The procedure is typically performed under ultrasound guidance and may offer appropriately selected patients a less invasive treatment option to conventional surgery.

Baird Medical's microwave ablation technology has been used in multiple countries and is designed to provide physicians with precise, minimally invasive treatment capabilities for selected soft tissue applications.

About Baird Medical

Baird Medical is a pioneering medical device company specializing in minimally invasive diagnostics, treatment, and surgical robotic systems. Driven by a mission to enhance patient outcomes through precision technology, the Company extends beyond surgical assistance, aiming to develop intelligent systems that proactively guide diagnostic decisions and preventive healthcare strategies.

As an FDA 510(k)-cleared medical device company, Baird Medical's solutions are utilized by over 30 prestigious U.S. institutions, including the Mayo Clinic, Columbia University Medical Center, UCSF Medical Center, and Weill Cornell Medical Center. Baird Medical is the market leader for thyroid microwave ablation devices in China and is rapidly expanding its commercial footprint across more than 20 countries. To fuel future innovation, the company actively fosters strategic collaborations with leading academic institutions worldwide.

Forward-Looking Statements

This press release includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or Baird Medical's future financial or operating performance. In some cases, you can identify forward-looking statements by terminology such as "may", "could", "should", "expect", "intend", "might", "will", "estimate", "anticipate", "believe", "budget", "forecast", "intend", "plan", "potential", "predict", or "continue", or the negatives of these terms or variations of them or similar terminology. Forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Baird Medical and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Baird Medical does not undertake any duty to update these forward-looking statements.

Actual results may vary materially from those expressed or implied by forward-looking statements based on a number of factors, including, without limitation: (1) the risk that Baird Medical may not be successful in expanding its business in China or the United States; (2) changes in general economic conditions; (3) regulatory conditions and developments; (4) changes in applicable laws or regulations; (5) the nature, cost and outcome of pending and future litigation and other legal proceedings instituted against Baird Medical or others; and (6) other risks and uncertainties from time to time described in the Registration Statement relating to the Business Combination and the transition report, including those listed under the sections titled "Risk Factors" therein, and in ExcelFin's other filings with the SEC.

The foregoing list of factors is not exclusive. Additional information concerning certain of these, and other risk factors is contained in ExcelFin's most recent filings with the SEC and in the Registration Statement described above filed by Baird Medical in connection with its business combination with ExcelFin. All subsequent written and oral forward-looking statements concerning Baird Medical, the business combination described herein or other matters attributable to Baird Medical or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Baird Medical expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in their expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

Contact:

Lee Roth
Burns McClellan for Baird Medical
Lroth@burnsmc.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/baird-medical-announces-first-microwave-ablation-procedures-using-its-technology-in-vietnam-and-argentina-302812431.html

SOURCE BDMD

FAQ

What did Baird Medical (NASDAQ: BDMD) announce on June 29, 2026?

Baird Medical announced the first clinical procedures using its microwave ablation technology in Vietnam and Argentina. According to Baird Medical, these landmark cases support its strategy to expand minimally invasive treatment options in new international markets.

Where were Baird Medical's first microwave ablation procedures performed in Vietnam and Argentina?

The first procedures took place in Vietnam and Argentina at leading hospitals. According to Baird Medical, Lac Viet Friendship Hospital treated a benign thyroid nodule, while Hospital General de Agudos Bernardino Rivadavia performed a liver ablation in Buenos Aires.

What medical conditions were treated using Baird Medical's microwave ablation technology in the first Vietnam and Argentina cases?

The initial cases treated a benign thyroid nodule in Vietnam and a liver lesion in Argentina. According to Baird Medical, both procedures used minimally invasive microwave ablation, aiming to offer selected patients an alternative to conventional surgery.

How does Baird Medical describe the benefits of its microwave ablation technology for patients?

Baird Medical highlights targeted treatment, minimal invasiveness, and little to no visible scarring as key benefits. According to Baird Medical, microwave ablation can also offer relatively short procedure and recovery times for appropriately selected patients compared with traditional surgical approaches.

Why are the first microwave ablation procedures in Vietnam and Argentina important for Baird Medical (BDMD)?

These procedures mark Baird Medical's entry into two additional international markets for its microwave ablation technology. According to Baird Medical, the cases support its global expansion strategy and deepen collaboration with clinical partners adopting minimally invasive therapies.

What role did physicians play in the first Baird Medical microwave ablation procedures in Vietnam and Argentina?

Experienced specialists led the first procedures in both countries using Baird Medical technology. According to Baird Medical, Dr. Dinh Xuan Ha performed the thyroid case in Vietnam, while Dr. Eduardo Houghton conducted the liver ablation in Buenos Aires.